Subscribe to our email list for the latest updates
November Monthly Report for Vivos Inc.
July 28, 2024
Vivos Inc. Provides IDE Submission Status
Update – Conversion to Pre-Sub Filing Accepted by the FDA
Latest News
Stay up-to-date with the latest developments at RadioGel™. From groundbreaking research to new product releases, our news section has everything you need to know about our company. Read the full press release here.
Vivos Inc. Submits IDE Application
Become a Part of the Future of RadioGel®
Are you creative and want to see your design on our new RadioGel™ T-Shirt as we begin to launch the RadioGel® division of Vivos Inc?
Revolutionizing Cancer Treatment
The Science Of RadioGel®
Precision Radionuclide Therapy™
The Science Of RadioGel®
Y-90 RadioGel™ is a device designed for radiation treatment of solid tumors. The Y-90 RadioGel™/Hydrogel mixture is injected directly and uniformly into tumors.
IDE Submission
Precision Radionuclide Therapy™
The Science Of RadioGel®
IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the RadioGel® Precision Radionuclide Therapy. To read the full press releases click here. Read the Press Release
RadioGel™ is currently not approved for human use.
Precision Radionuclide Therapy™
Precision Radionuclide Therapy™
Precision Radionuclide Therapy™
Also known as PRnT™, the treatment uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area, delivering therapeutic radiation from within the tumor.
Meet The Team
The RadioGel® Blog
Precision Radionuclide Therapy™
We are a team dedicated to developing a safer, less invasive cancer treatment for humans and animals worldwide.
Stay Informed
The RadioGel® Blog
The RadioGel® Blog
Sign up to have the latest press releases sent directly to your inbox.